H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Wave Life Sciences (WVE) to $18 from $30 and keeps a Buy rating on the shares. The firm believes the market’s “overreaction” misinterprets WVE-007’s potential, saying low baseline mass body indexes likely limited the observable potency of the INHBE/ALK7 pathway.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
- Wave Life Sciences price target lowered to $15 from $27 at RBC Capital
- Baozun, Pony AI, Agree Realty, Spruce, Wave Shock
- Wave Life Sciences removed from Best Ideas List at Wedbush
- Wave Life Sciences price target lowered to $21 from $38 at BofA